Pharmacotherapy for Stimulant Use Disorders Management Briefs eBrief-no147 -- Pharmacotherapy for Stimulant Use Disorders Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no147 -- Pharmacotherapy for Stimulant Use Disorders Health Services Research & Development Management eBrief no. 147 » Issue 147 October 2018 The report is a product of the VA/HSR&D Evidence Synthesis Program (...) . Pharmacotherapy for Stimulant Use Disorders: A Systematic Review Stimulant use disorders, specifically cocaine and methamphetamine use disorders, present ongoing public health problems in the United States, with major medical, psychiatric, cognitive, socioeconomic, and legal consequences. There are more emergency department visits associated with cocaine compared with other illicit substances, and several US cities consider methamphetamine as the drug of abuse associated with the "most serious consequences

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Among US adults, utilization of pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) has increased more than ninefold since 1995-1996. Potential contraindications to ADHD pharmacotherapy include serious cardiovascular disease (CVD) and, for stimulants, addictions and bipolar disorder (BPD).To assess the prevalence (...) of potential contraindications among adults treated with ADHD pharmacotherapy.A retrospective cohort analysis was performed using the Truven Health MarketScan® database. Subjects filled ≥ 1 prescription for atomoxetine or ≥ 1 stimulant in 2014-2015, were aged 18-64 years, commercially insured throughout observation, and diagnosed with ADHD on two or more medical claims. Diagnoses and medical procedures were measured in the 12 months prior to pharmacotherapy initiation. Metrics included serious CVD

Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders Stimulant medication for ADHD not associated with subsequent substance use disorders | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stimulant medication for ADHD not associated with subsequent substance use disorders Article Text Aetiology Systematic review with meta-analysis Stimulant medication for ADHD

Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis Historical clinical (...) and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis Naci H, de Lissovoy G, Hollenbeak C, Custer B, Hofmann A, McClellan W, Gitlin M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

Therapeutic use of Transcutaneous Electrical Nerve Stimulators for Temporomandibular Joint Disorder pain relief UTCAT809, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Therapeutic Use Of Transcutaneous Electrical Nerve Stimulators For Temporomandibular Joint Disorder Pain Relief Clinical Question In a 40 year old female with chronic TMD, does TENS (Transcutaneous Electrical Nerve Stimulators) provide better symptom (...) . There have not been enough stringent studies with a comparison using a gold standard. Therefore, at this time it would be difficult to make any conclusions as to the efficacy of TENS in TMD related illness. Evidence Search Search temporomandibular joint disorder pain management Limits: Humans, Randomized Controlled Trial, EnglishSearch temporomandibular joint disorder pain management Limits: Humans, Meta-Analysis, EnglishSearch temporomandibular joint disorder alternative treatment Limits: Humans, Meta

Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. To compare the effectiveness of an electrocautery strategy with ovulation induction using recombinant follicle stimulating hormone in patients with polycystic ovary syndrome.Randomised controlled trial.Secondary and tertiary hospitals in the Netherlands.168 patients with clomiphene citrate resistant polycystic ovary syndrome: 83 were (...) allocated electrocautery and 85 were allocated recombinant follicle stimulating hormone.Laparoscopic electrocautery of the ovaries followed by clomiphene citrate and recombinant follicle stimulating hormone if anovulation persisted, or induction of ovulation with recombinant follicle stimulating hormone.Ongoing pregnancy within 12 months.. The cumulative rate of ongoing pregnancy after recombinant follicle stimulating hormone was 67%. With only electrocautery it was 34%, which increased to 49% after

Spinal cord stimulation: use in patients with complex regional pain syndrome Spinal cord stimulation: use in patients with complex regional pain syndrome Spinal cord stimulation: use in patients with complex regional pain syndrome WCB Evidence Based Practice Group Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation WCB Evidence Based Practice Group. Spinal cord (...) stimulation: use in patients with complex regional pain syndrome. Richmond, BC: WorkSafe BC 2003: 26 Authors' objectives This study examines spinal cord stimulation and its use in patients with complex regional pain syndrome. Authors' conclusions MEDICAL EVIDENCE - CONCLUSIONS 1. Twenty-five workers have had spinal cord stimulation (SCS) implantation approved by the WCB up to October 17, 2002. Thirteen of these had complex regional pain syndrome (CRPS), while twelve workers had other diagnoses